title: [Retinal and choroidal thickness changes following intravitreal ranibizumab injection for exudative age-related macular degeneration].
abstract: OBJECTIVE
  To evaluate the retinal and choroidal thickness changes following intravitreal ranibizumab injection (IVR) for exudative age-related macular degeneration (AMD).
  
  
  METHODS
  Twenty-eight eyes of 28 patients (average age 72.2) with newly diagnosed AMD (typical AMD 24 and PCV 4) were retrospectively examined during a 1-year follow-up. All cases first received 3 consecutive monthly injections and thereafter pro re nata (PRN) retreatment. Central retinal thickness and subfoveal choroidal thickness were measured before and 1, 3, 6 and 12 months after initial treatment using optical coherence tomography.
  
  
  RESULTS
  The average number of injections was 5.2 times. Mean central retinal thickness significantly decreased from 456 microm at baseline to 337 microm 1 month after IVR and 280 microm 1-year after initial IVR (respectively, p<0.01). Mean subfoveal choroidal thickness was 225 microm (typical AMD was 227 microm at baseline) at baseline, 225 microm 6 months after initial IVR and 220 microm 1-year after initial IVR. There was no significant difference compared to baseline (p = 0.78 and 0.45).
  
  
  CONCLUSIONS
  Although central retinal thickness of AMD decreased even 1-year after initial IVR, subfoveal choroidal thickness remained at 6 months and 1-year after initial IVR. Subfoveal choroidal thickness of AMD is less affected by IVR in the long term.
authors: Department of Ophthalmology, Fukushima Medical University School of Medicine, Japan mogasawara2@yahoo.co.jp
authors: Masashi
authors: M
authors: Ogasawara
authors: Ichiro
authors: I
authors: Maruko
authors: Yukinori
authors: Y
authors: Sugano
authors: Akira
authors: A
authors: Ojima
authors: Tetsuju
authors: T
authors: Sekiryu
authors: Tomohiro
authors: T
authors: Iida
mesh_terms: D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000494:pharmacology; D002829:Choroid / Q000187:drug effects*; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D008268:Macular Degeneration; D008297:Male; D000069579:Ranibizumab; D012160:Retina / Q000187:drug effects*; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab